New epigenetic drug against Mantle Cell Lymphoma
Share

IMAGE: These are cells of a patient with mantle lymphoma before (left image) and after (right image) of treatment with the drug. Inhibition of cell growth is observed. view more 

Credit: IDIBELL

A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of Barcelona, presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL), a type of cancer characterized by its aggressive behavior, its delayed diagnosis with affectation of different organs and its origin from the lymphocytes B. The research results, published in Haematologica, the European Hematology Society (EHA) scientific journal, may be an answer to current medical need for new treatments that increase long-term survival in this disease.

“Our laboratory is interested in finding new compounds with epigenetic activity and anti-tumor effects. Working together with organic chemists and the Quimatryx company we obtained a molecule that inhibits the HDAC6 gene, a protein that chemically modifies another protein by acetylation”, says Manel Esteller, main author of the study. The research has also been carried out with the clinical collaboration of the Hematology

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD